Item 9 Labs Corp. Announces Second Quarter FY 2022 Financial Results with Revenue Growth of 9% to $6.6 Million
Item 9 Labs Corp. (OTCQX: INLB) reported its fiscal Q2 FY2022 results, revealing a 9% revenue increase to $6.6 million. Despite this growth, the company faced an operating loss of $2.8 million and a net loss of $3.9 million, compared to a net income of $50,000 the previous year. The expansion continues with Unity Rd. dispensaries entering South Dakota, New Mexico, and Oklahoma. The Nevada cultivation site is nearing completion, and Arizona's development is on track. Management will discuss these results in a conference call held today.
- Revenue increased 9% to $6.6 million.
- Expansion into three new states for Unity Rd. dispensaries.
- Strong gross margin at approximately 40%.
- Operating loss of $2.8 million compared to operating income of $0.5 million.
- Net loss of $3.9 million compared to net income of $50,000.
- Adjusted EBITDA loss of $0.9 million compared to a profit of $1 million.
- National Unity Rd. Dispensary Franchise Footprint Expands into Three New States
- Cultivation, Production and Processing Expansion in Nevada Nears Completion with Phase One of Arizona Development also on Track
- Management to Host Conference Call and Webcast to Discuss Key Operational and Financial Highlights Today at 4:30 p.m. ET
PHOENIX, May 16, 2022 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—today reported its fiscal second quarter operating and financial results for the three months ended March 31, 2022.
"Last year, our team focused on strengthening our position for future growth, both locally in Arizona and nationally across the U.S.," said Item 9 Labs Corp.'s Chief Executive Officer, Andrew Bowden. "The momentum we've achieved over the past quarter demonstrates the power of this foundation and gives a glimpse into what's ahead for our national growth and product excellence."
Key Business Highlights During Q2 FY2022 (January 1 - March 31, 2022)
- Expanded Unity Rd. dispensary franchise into three new markets – securing dispensary licenses in South Dakota and New Mexico as well as partnering with an existing dispensary in Oklahoma that is expected to be converted soon into a Unity Rd. shop.
- Actively growing the Unity Rd. national footprint through accretive acquisitions of existing dispensaries that it intends will be converted into Unity Rd. shops.
- Recent acquisition activity in the Denver market with the closing of an acquisition in Adams County, Colorado and an Asset Purchase Agreement for a medicinal and recreational dispensary and cultivator operating in the desirable Washington Park neighborhood of Denver.
- Item 9 Labs' Orion 710 series has been making waves throughout the Arizona market, sweeping the best indica and best sativa cannabis vape categories at Arizona's Spring ERRL Cup in March.
- Cultivation site in Pahrump, Nevada is almost completed.
- Phase one of the Coolidge, Arizona master site development remains on track with a target completion date this summer.
- Added franchising veteran Shane Evans to board of directors.
Bowden continued, "Focusing on execution sums up our plan for 2022 as we continue our mission to keep the door to cannabis entrepreneurship open to the everyday entrepreneur and bring more high-quality, alternative medicine to consumers nationwide. As large equity holders, our goals remain aligned with our shareholders in creating long-term value and brands that are built to last."
Key Financial Highlights for Q2 FY2022 (compared with Q2 FY2021)
- Revenue increased
9% to$6.6 million - Gross profit totaled
$2.7 million - Gross margin remained strong at approximately
40% - Operating loss of
$2.8 million compared with operating income of$0.5 million - Net loss of
$3.9 million compared with net income of$50 thousand - Net loss included
$1.1 million ($255 ,000 paid in cash) of interest expense compared with $.5 million ($143 ,000 paid in cash) - Adjusted EBITDA loss of
$0.9 million compared with adjusted EBITDA profit of$1.0 million (invested significantly in franchise expenses, human capital, and infrastructure for expansion) - Cash and cash equivalents totaled
$0.1 million as of March 31, 2022 - Escrow deposits of
$10.1 million in cash set aside for expansion as of March 31, 2022
Conference Call and Webcast Information – Tuesday, May 16, 2022 at 4:30 p.m. ET (1:30 p.m. PT)
Item 9 Labs Corp.'s Chief Executive Officer Andrew Bowden and Chief Financial Officer Bobby Mikkelsen will host the Company's Q2 FY2022 results call.
- Date: Monday, May 16, 2022
- Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
- Access by Zoom: A live and archived webcast will be available via Sequire, click on this webcast link to register or access the replay.
- Access by Phone: Please call the conference telephone number 10-15 minutes prior to the start time: Dial-in number: 669-900-6833 // Meeting ID: 96267842685 // Passcode: 389480
- Questions: Please submit questions to investors@item9labscorp.com before the presentation begins. The management team will do their best to answer all questions.
ITEM 9 LABS CORP. AND SUBSIDIARIES | ||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||
March 31, | September 30, | |||
2022 | 2021 | |||
(unaudited) | ||||
ASSETS | ||||
Current Assets: | ||||
Cash and cash equivalents | $ 105,128 | $ 1,454,460 | ||
Accounts receivable, net | 1,177,003 | 1,448,280 | ||
Inventory | 4,819,619 | 6,391,351 | ||
Prepaid expenses and other current assets | 782,556 | 802,558 | ||
Total current assets | 6,884,306 | 10,096,649 | ||
Property and equipment, net | 24,009,739 | 10,877,848 | ||
Right of use asset | 730,516 | 156,938 | ||
Construction escrow deposits | 10,096,928 | 17,744,913 | ||
Deposits | 98,701 | 600,000 | ||
Other assets | 1,229,940 | 608,874 | ||
Intangible assets, net | 19,590,433 | 18,659,095 | ||
Goodwill | 58,233,386 | 58,064,816 | ||
Total Assets | $ 116,809,133 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
Current Liabilities: | ||||
Accounts payable | $ 5,522,921 | $ 3,759,818 | ||
Accrued payroll and payroll taxes | 2,646,036 | 2,678,694 | ||
Accrued interest | 1,792,925 | 1,391,766 | ||
Accrued expenses | 1,241,683 | 1,169,776 | ||
Deferred revenue, current portion | 219,992 | 119,992 | ||
Notes payable, current portion, net of discounts | 21,136,912 | 4,536,002 | ||
Income tax payable | 3,324 | - | ||
Operating lease liability, current portion | 219,773 | 56,592 | ||
Convertible notes payable, net of discounts | 2,815,880 | 1,277,394 | ||
Total current liabilities | 35,599,446 | 14,990,034 | ||
Deferred revenue, net of current portion | 345,855 | 655,851 | ||
Operating lease liability, net of current portion | 518,520 | 104,406 | ||
Notes payables, net of current portion and discounts | 1,645,043 | 14,957,399 | ||
Total liabilities | 38,108,864 | 30,707,690 | ||
Commitments and Contingencies | ||||
Stockholders' Equity: | ||||
Common stock, par value $.0001 per share, 2,000,000,000 shares authorized; 108,269,428 and 107,074,417 shares issued and 95,969,428 and 94,774,417 shares outstanding at March 31, 2022 and September 30, 2021, respectively | 10,827 | 10,707 | ||
Additional paid-in capital | 137,280,385 | 133,414,830 | ||
Accumulated deficit | (41,097,186) | (33,874,094) | ||
Treasury stock | (13,450,000) | (13,450,000) | ||
Total Item 9 Labs Corp. Stockholders' Equity | 82,744,026 | 86,101,443 | ||
Non-controlling interest | 21,059 | - | ||
Total Stockholders' Equity | 82,765,085 | 86,101,443 | ||
Total Liabilities and Stockholders' Equity | $ 116,809,133 | |||
ITEM 9 LABS CORP. AND SUBSIDIARIES | ||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
For the three months ended | For the three months ended | For the six months ended | For the six months ended | |||||
March 31, 2022 | March 31, 2021 | March 31, 2022 | March 31, 2021 | |||||
Revenues, net | $ 6,638,186 | $ 6,110,631 | $ 12,824,197 | $ 9,150,195 | ||||
Cost of revenues | 3,960,948 | 3,121,045 | 7,748,193 | 4,729,176 | ||||
Gross profit | 2,677,238 | 2,989,586 | 5,076,004 | 4,421,019 | ||||
Operating expenses | ||||||||
Professional fees and outside services | 556,721 | 613,758 | 1,214,166 | 907,713 | ||||
Payroll and employee related expenses | 3,055,244 | 1,318,842 | 5,205,950 | 2,422,146 | ||||
Sales and marketing | 613,902 | 84,165 | 1,053,338 | 127,346 | ||||
Depreciation and amortization | 442,477 | 105,897 | 881,612 | 248,442 | ||||
Other operating expenses | 786,167 | 349,517 | 1,632,835 | 564,054 | ||||
Provision for (recovery of) bad debt | (5,000) | - | (5,000) | - | ||||
Total expenses | 5,449,511 | 2,472,179 | 9,982,901 | 4,269,701 | ||||
Income (loss) from operations | (2,772,273) | 517,407 | (4,906,897) | 151,318 | ||||
Other income (expense) | ||||||||
Interest expense | (1,097,373) | (468,387) | (2,307,763) | (1,176,754) | ||||
Other income | 318 | - | 318 | - | ||||
Total other income (expense), net | (1,097,055) | (468,387) | (2,307,445) | (1,176,754) | ||||
Net income (loss), before income tax provision (benefit) | (3,869,328) | 49,020 | (7,214,342) | (1,025,436) | ||||
Income tax provision (benefit) | 3,324 | - | 3,324 | - | ||||
Net income (loss) | (3,872,652) | 49,020 | (7,217,666) | (1,025,436) | ||||
Less: Net income attributable to non-controlling interest | 5,426 | - | 5,426 | - | ||||
Net income (loss) attributable to Item 9 Labs Corp. | $ (3,878,078) | $ 49,020 | $ (7,223,092) | $ (1,025,436) | ||||
Basic net income (loss) per common share | $ (0.04) | $ 0.00 | $ (0.08) | $ (0.02) | ||||
Basic weighted average common shares outstanding | 95,271,726 | 65,880,141 | 95,088,960 | 62,143,521 | ||||
Diluted net income (loss) per common share | $ (0.04) | $ 0.00 | $ (0.08) | $ (0.02) | ||||
Diluted weighted average common shares outstanding | 95,271,726 | 84,938,235 | 95,088,960 | 62,143,521 | ||||
ITEM 9 LABS CORP. AND SUBSIDIARIES | |||||||
ADJUSTED EBITDA | |||||||
Three months ended March 31, | Six months ended March 31, | ||||||
2022 | 2021 | 2022 | 2021 | ||||
Net income (loss) | $ 49,020 | ||||||
Depreciation and amortization | 442,477 | 105,897 | 881,612 | 248,442 | |||
Interest expense | 1,097,373 | 468,387 | 2,307,763 | 1,176,754 | |||
Income tax expense | 3,324 | - | 3,324 | - | |||
Stock-based expense | 1,363,485 | 304,672 | 1,870,779 | 772,580 | |||
Acquisition related costs | 23,676 | 87,060 | 23,676 | 266,738 | |||
Adjusted EBITDA | $ (942,317) | $ 1,439,078 | |||||
About Item 9 Labs Corp.
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space up to 640,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.
Use of Non-GAAP Financial Measures
To supplement the Company's financial statements presented on a GAAP basis, Item 9 Labs Corp. provides Adjusted EBITDA as a supplemental measure of its performance. To provide investors with additional insight and allow for a more comprehensive understanding of the information used by management in its financial and decision-making surrounding pro forma operations, Item 9 Labs Corp. supplements its consolidated financial statements presented on a basis consistent with U.S. generally accepted accounting principles, or GAAP, with Adjusted EBITDA as a non-GAAP financial measure of earnings. Adjusted EBITDA represents EBITDA plus stock-based compensation and acquisition related expenses. Item 9 Labs Corp. management uses Adjusted EBITDA as a financial measure to evaluate the profitability and efficiency of the business model. The Company uses these non-GAAP financial measures to assess the strength of the underlying operations of the business. These adjustments, and the non-GAAP financial measures that are derived from them, provide supplemental information to analyze its operations between periods and over time. Item 9 Labs Corp. finds this especially useful when reviewing pro forma results of operations, which include large non-cash amortizations of intangible assets from acquisitions and stock-based compensation. Investors should consider its non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact:
Item 9 Labs Corp.
Jayne Levy, VP of Communications
Email: Jayne@item9labs.com
Investor Contact:
Item 9 Labs Corp.
800-403-1140
Email: investors@item9labscorp.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/item-9-labs-corp-announces-second-quarter-fy-2022-financial-results-with-revenue-growth-of-9-to-6-6-million-301548294.html
SOURCE Item 9 Labs Corp.
FAQ
What were the financial results for Item 9 Labs Corp. in Q2 FY2022?
What is the revenue growth percentage for Item 9 Labs Corp. in Q2 FY2022?
How much cash did Item 9 Labs Corp. have as of March 31, 2022?
When is the conference call to discuss Item 9 Labs Corp.'s Q2 FY2022 results?
What are the expansion plans for Item 9 Labs Corp.?
